EUVIMEDEUVIMED entdecken
Open Access

Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes

Dade Feng, Huiting Yan, Qian Ni, Zirui Peng, Xiong Xu, Yanfang Liang, Chongmei Liu

Oncology Research · 2026

DOI: 10.32604/or.2026.087712 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Dade Feng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Yueyang People's Hospital of Hunan Normal University, Yueyang, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Adenocarcinoma of Lung, Lung Neoplasms, Epigenesis, Genetic. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmAdenocarcinoma of LungLung NeoplasmsEpigenesis, GeneticAcrylamidesAniline Compounds3-Hydroxybutyric AcidHumansAnimalsDNA MethylationIndolesPyrimidinesCell Line, TumorMiceGene Expression Regulation, NeoplasticGene SilencingPhenotypeFemaleXenograft Model Antitumor AssaysPromoter Regions, GeneticSignal Transduction

Stichwörter der Autor:innen

DNA methylationLung adenocarcinomaPI3K/AKT/mTORosimertinib resistancezinc finger protein 471 (ZNF471)β-hydroxybutyrate

Substanzen

osimertinibIndolesPyrimidinesAcrylamidesAniline Compounds3-Hydroxybutyric Acid

Autor:innen und Institutionen

  • Department of Pathology, Yueyang People's Hospital of Hunan Normal University, Yueyang, China.
  • School of Basic Medical Sciences, Hunan Normal University Health Science Center, Hunan Normal University, Changsha, China.
  • Department of Orthopedics, Yueyang People's Hospital of Hunan Normal University, Yueyang, China.
  • Department of Science and Education, Yueyang People's Hospital of Hunan Normal University, Yueyang, China.

Zitieren

APA

Feng, D., Yan, H., Ni, Q., Peng, Z., Xu, X., Liang, Y., & Liu, C. (2026). Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes. Oncology Research. https://doi.org/10.32604/or.2026.087712

Vancouver

Feng D, Yan H, Ni Q, Peng Z, Xu X, Liang Y, et al. Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes. Oncology Research. 2026. doi:10.32604/or.2026.087712

BibTeX
@article{Feng2026,
  author = {Feng, Dade and Yan, Huiting and Ni, Qian and Peng, Zirui and Xu, Xiong and Liang, Yanfang and Liu, Chongmei},
  title = {Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes},
  journal = {Oncology Research},
  year = {2026},
  doi = {10.32604/or.2026.087712}
}
Kostenlos starten →